BJERKHOLT ERIC 4

What Happened

• Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals (MIRM), executed open-market sales of 5,000 shares on June 8, 2026 for a total of $469,077, and on June 9, 2026 exercised options to acquire 2,393 shares at $26.49 per share (total exercise cost $63,391).
• Sales were reported as open market transactions; the exercise is reported under Form 4 code M (exercise/conversion of derivative). The filing also shows a simultaneous disposition of 2,393 derivative shares at $0 (see Context).

Key Details

• Sale(s) on 2026-06-08: 2,258 shares @ weighted avg $92.84 (range $92.485–$93.31) = $209,633; 1,175 shares @ weighted avg $93.95 (range $93.49–$94.47) = $110,391; 1,567 shares @ weighted avg $95.12 (range $94.62–$95.44) = $149,053. Total sold = 5,000 shares for $469,077.
• Exercise on 2026-06-09 (code M): acquired 2,393 shares @ $26.49 = $63,391. A simultaneous line reports disposition of 2,393 derivative shares at $0.
• Shares owned after the transactions: not specified in the excerpt provided. (See the filing for full ownership totals.)
• Notable footnotes: sales occurred pursuant to a Rule 10b5-1 trading plan adopted March 9, 2026 (F1). Sale price weighted averages and ranges are provided in the filing (F2–F4). Vesting schedule noted for related awards (F5).
• Filing date: 2026-06-09 for transactions on 2026-06-08/09 — appears to be timely (not marked late).

Context

• The filing shows an option exercise (acquisition) and an equal-number disposition reported the same day at $0. That pattern often reflects net-share settlement or withholding related to option exercises or taxes; the filing itself does not provide further detail.
• Sales under a 10b5-1 plan are pre-arranged trading programs and are generally considered routine; purchases or exercises can be more informative, but this filing is primarily a sale by the CFO combined with an option exercise.
• This summary is factual — it does not infer motivations. For complete details (ownership after the trade, exact allocation of sale prices, and any tax or net-settlement mechanics), refer to the full Form 4 filing (Accession 0001197350-26-000007).